Society of Diabetic Nephropathy Prevention Journal of Nephropathology 2251-8363 8 4 2019 10 01 Does fibroblast growth factor 23 correlates with volume status in hemodialysis patients? e35 e35 10.15171/jnp.2019.35 EN Farzanehsadat Minoo https://orcid.org/0000-0002-3994-8427 Azam Alamdari https://orcid.org/0000-0002-5319-8183 Hamed Karimi Journal Article 10.15171/jnp.2019.35 2019 11 04 2019 01 09 Introduction: Volume overload is a known risk factor for cardiovascular disease and stroke in hemodialysis patients. The use of fibroblast growth factor 23 (FGF23) as a volume overload marker has been validated in multiple studies. Objectives: This is a prospective cross-sectional study considering the association between FGF23 and bioimpedance-measured volume overload in hemodialysis patients. Patients and Methods: Bioimpedance analysis was performed on 43 hemodialysis patients at the end of hemodialysis to evaluate the remaining volume overload and serum FGF23 was measured before hemodialysis. Results: The results indicated no significant correlation between mean serum FGF23 levels and volume overload in hemodialysis patients (P=0.824). Conclusion: Although this study did not show any association between volume overload and FGF23, further studies are needed to define the role of FGF23 as a volume overload marker.